Fully integrated platform launches for DCTs


 A fully integrated patient-centric platform has been launched to help optimise the management of hybrid and decentralised clinical trials (DCT).   

The platform  

The platform, developed by Kayentis, has been designed to help clinical trials providers overcome the logistical hurdles faced when bringing trials to patients’ homes, whilst also improving how patients and sites use DCT technologies.  

Through the platform, stakeholders working in remote clinical trials gain access to a range of functionalities including, data collection, provisioned devices, data entry by phone, and a telemedicine app.  

By having a single, integrated platform, Kayentis is able to provide sponsors with a single set-up of functionalities, potentially giving them better sponsor lead times. For patients, Kayentis hopes that through a single, digital access, the platform will improve patient compliance, retention, and the quality of data collected.   

The platform also includes a media playing tool so patients and sites can access training modules, user tools and guides and other educational resources. More so, a study participant feedback questionnaire module allows study patients to remotely provide feedback on their clinical trial experience.   

Official comments

“Kayentis’ new streamlined platform features make remote clinical trials much easier for patients, sites, CROs and sponsors to manage; the simplified access to options considerably reduces patient burden,” said Guillaume Juge, CEO at Kayentis. “We have been expanding our DCT services in step with the growing demand for hybrid and decentralised clinical trials. This added capacity enables our operational teams across Europe, the US and Asia to attract wider interest in our digital capabilities.”  

“Kayentis’ platform is applicable in all therapeutic areas, particularly complex protocols, and in all clinical trial models: traditional, virtual or hybrid clinical trials. The value in this new platform lies in its ability to expand the choice of interconnectable options, while standardizing the same enhanced user experience across multiple systems (Web, Google Android, Apple iOS),” added Martial Marcotti, product marketing director at Kayentis.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free